

# Injectable silicone biomaterial (PTQTM) is more effective than carbon-coated beads (Durasphere®) in treating passive faecal incontinence: a randomised trial

<b>Submission date</b> 22/05/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 09/06/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 10/06/2008	<b>Condition category</b> Signs and Symptoms	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Miranda Chan

### Contact details

Caritas Medical Centre, 111

Wing Hong Street

Shum Shui Po

Hong Kong

Hong Kong

-

+852 3408 7785

mirchan@hotmail.com

## Additional identifiers

## Study information

Scientific Title

**Study objectives**

To compare safety and efficacy of PTQTM compared with Durasphere® in treating patients with passive faecal incontinence.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved by the Human Resource Ethics Committee of Epworth Hospital

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Passive faecal incontinence

**Interventions**

Injectable bulking agents to augment the bulk of the internal anal sphincter: injectable silicone biomaterial (PTQTM) vs carbon-coated beads (Durasphere®).

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

PTQTM, Durasphere®

**Primary outcome(s)**

Wexners continence score, assessed at 2 and 6 weeks, then 6 and 12 months after treatment

**Key secondary outcome(s)**

The following were assessed at 2 and 6 weeks, then 6 and 12 months after treatment:

1. Faecal incontinence quality of life (FIQL) scale
2. Short Form 12 (SF-12) health survey questionnaire
3. Adverse events

**Completion date**

31/10/2006

**Eligibility****Key inclusion criteria**

1. Both males and females, no age limits
2. Faecal seepage or soiling for more than twice a week caused by internal sphincter (IAS) dysfunction
3. Not responding to treatment with dedicated pelvic floor exercises and stool bulking agents

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Other

**Sex**

All

**Key exclusion criteria**

1. Perianal sepsis
2. Anorectal cancer
3. Immunosuppression
4. Rectal prolapse
5. Inflammatory bowel disease
6. Congenital anorectal malformation
7. Neurological disorders such as Parkinsons disease
8. Multiple sclerosis
9. Spinal-cord injury
10. Stoma in situ
11. Pregnancy
12. External anal sphincter defect of more than 120° of the circumference
13. Bleeding diathesis,
14. Mental or physical disability precluding adherence to study protocol

**Date of first enrolment**

01/08/2005

**Date of final enrolment**

31/10/2006

**Locations****Countries of recruitment**

Australia

Hong Kong

**Study participating centre**

Caritas Medical Centre, 111  
Hong Kong

Hong Kong

-

## Sponsor information

### Organisation

Epworth Hospital, University of Melbourne (Australia)

### ROR

<https://ror.org/01ej9dk98>

## Funder(s)

### Funder type

Not defined

### Funder Name

Not provided at time of registration

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration